7 results on '"Kuse, Rolf"'
Search Results
2. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma
- Author
-
Kröger, Nicolaus, Schwerdtfeger, Rainer, Kiehl, Michael, Sayer, Herbert Gottfried, Renges, Helmut, Zabelina, Tatjana, Fehse, Boris, Tögel, Florian, Wittkowsky, Georg, Kuse, Rolf, and Zander, Axel Rolf
- Published
- 2002
- Full Text
- View/download PDF
3. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
- Author
-
Huhn, Dieter, von Schilling, Christoph, Wilhelm, Martin, Ho, Anthony D., Hallek, Michael, Kuse, Rolf, Knauf, Wolfgang, Riedel, Ute, Hinke, Axel, Srock, Stefanie, Serke, Stefan, Peschel, Christian, and Emmerich, Bertold
- Published
- 2001
- Full Text
- View/download PDF
4. Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
- Author
-
Dietz, Christian T., Fabarius, Alice Charlotte, Lauseker, Michael, Saussele, Susanne, Kalmanti, Lida, Rinaldetti, Sebastien, Haferlach, Claudia, Schlegelberger, Brigitte, Jotterand, Martine, Gratwohl, Alois, Zander, Axel R., Kroeger, Nicolaus, Beelen, Dietrich W., Novotny, Juergen, Nerl, Christoph, Scheid, Christof, Spiekermann, Karsten, Mayer, Jiri, Sayer, Herbert G., Falge, Christiane, Bunjes, Donald, Doehner, Hartmut, Ganser, Arnold, Brossart, Peter, Schwerdtfeger, Rainer, Baumann, Herrad, Kuse, Rolf, Lindemann, Hans Walter, Bormann, Matthias, Hertenstein, Bernd, Baerlocher, Gabriela M., Aul, Carlo, Staib, Peter, Edinger, Matthias, Schatz, Michael, Fauser, Axel A., Arnold, Renate, Hossfeld, Dieter K., Kolb, Hans-Jochem, Schnittger, Susanne, Mueller, Martin C., Reiter, Andreas, Hochhaus, Andreas, Pfirrmann, Markus, Hasford, Joerg, Baccarani, Michele, Hehlmann, Ruediger, Dietz, Christian T., Fabarius, Alice Charlotte, Lauseker, Michael, Saussele, Susanne, Kalmanti, Lida, Rinaldetti, Sebastien, Haferlach, Claudia, Schlegelberger, Brigitte, Jotterand, Martine, Gratwohl, Alois, Zander, Axel R., Kroeger, Nicolaus, Beelen, Dietrich W., Novotny, Juergen, Nerl, Christoph, Scheid, Christof, Spiekermann, Karsten, Mayer, Jiri, Sayer, Herbert G., Falge, Christiane, Bunjes, Donald, Doehner, Hartmut, Ganser, Arnold, Brossart, Peter, Schwerdtfeger, Rainer, Baumann, Herrad, Kuse, Rolf, Lindemann, Hans Walter, Bormann, Matthias, Hertenstein, Bernd, Baerlocher, Gabriela M., Aul, Carlo, Staib, Peter, Edinger, Matthias, Schatz, Michael, Fauser, Axel A., Arnold, Renate, Hossfeld, Dieter K., Kolb, Hans-Jochem, Schnittger, Susanne, Mueller, Martin C., Reiter, Andreas, Hochhaus, Andreas, Pfirrmann, Markus, Hasford, Joerg, Baccarani, Michele, and Hehlmann, Ruediger
- Published
- 2015
5. Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
- Author
-
Dietz, Christian T., primary, Fabarius, Alice Charlotte, additional, Lauseker, Michael, additional, Saussele, Susanne, additional, Kalmanti, Lida, additional, Rinaldetti, Sébastien, additional, Haferlach, Claudia, additional, Schlegelberger, Brigitte, additional, Jotterand, Martine, additional, Gratwohl, Alois, additional, Zander, Axel R., additional, Kröger, Nicolaus, additional, Beelen, Dietrich W., additional, Novotny, Jürgen, additional, Nerl, Christoph, additional, Scheid, Christof, additional, Spiekermann, Karsten, additional, Mayer, Jiri, additional, Sayer, Herbert G., additional, Falge, Christiane, additional, Bunjes, Donald, additional, Döhner, Hartmut, additional, Ganser, Arnold, additional, Brossart, Peter, additional, Schwerdtfeger, Rainer, additional, Baumann, Herrad, additional, Kuse, Rolf, additional, Lindemann, Hans Walter, additional, Bormann, Matthias, additional, Hertenstein, Bernd, additional, Baerlocher, Gabriela M., additional, Aul, Carlo, additional, Staib, Peter, additional, Edinger, Matthias, additional, Schatz, Michael, additional, Fauser, Axel A, additional, Arnold, Renate, additional, Hossfeld, Dieter K., additional, Kolb, Hans-Jochem, additional, Schnittger, Susanne, additional, Müller, Martin C., additional, Reiter, Andreas, additional, Hochhaus, Andreas, additional, Pfirrmann, Markus, additional, Hasford, Joerg, additional, Baccarani, Michele, additional, and Hehlmann, Ruediger, additional
- Published
- 2015
- Full Text
- View/download PDF
6. Improved Outcome in Adult B-Cell Acute Lymphoblastic Leukemia
- Author
-
Hoelzer, Dieter, Ludwig, Wolf-Dieter, Thiel, Eckhard, Gaßmann, Winfried, Loffler, Helmut, Fonatsch, Christa, Rieder, Harald, Heil, Gerhard, Heinze, Barbara, Arnold, Renate, Hossfeld, Dieter, Buchner, Thomas, Koch, Peter, Freund, Matthias, Hiddemann, Wolfgang, Maschmeyer, Georg, Heyll, Axel, Aul, Carlo, Faak, Thomas, Kuse, Rolf, Ittel, Thomas H., Gramatzki, Martin, Diedrich, Helmut, Kolbe, Katrin, Fuhr, Heinz-Georg, Fischer, Konstanze, Schadeck-Gressel, Claire, Weiss, Adelheid, Strohscheer, Imke, Metzner, Bernd, Fabry, Ursula, Gökbuget, Nicola, Völkers, Bernd, Messerer, Dorle, and überla, Karl
- Abstract
A total of 68 adult patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated in three consecutive adult muhicenter ALL studies. The diagnosis of B-ALL was confirmed by L3 morphology and/or by surface immunoglobulin (Slg) expression with >25% blast cell infiltration in the bone marrow (BM). They were characterized by male predominance (78%) and a median age of 34 years (15 to 65y) with only 9% adolescents (15 to 20y), but 28% elderly patients (50 to 65y). The patients received either a conventional (N = 9) ALL treatment regimen (ALL study 01/81) or protocols adapted from childhood B-ALL with six short, intensive 5-day cycles, alternately A and B. In study B-NHL83 (N = 24) cycle A consisted of fractionated doses of cyclophosphamide 200 mg/m2for 5 days, intermediate-dose methotrexate (IdM) 500 mg/m2(24 hours), in addition to cytarabine (AraC), teniposide (VM26) and prednisone. Cycle B was similar except that AraC and VM26 were replaced by doxorubicin. Major changes in study B-NHL86 (N = 35) were replacement of cyclophosphamide by ifosphamide 800 mg/m2for 5 days, an increase of IdM to high-dose, 1,500 mg/m2(HdM) and the addition of vincristine. A cytoreductive pretreatment with cyclophosphamide 200 mg/m2, and prednisone 60 mg/m2, each for 5 days was recommended in study B-NHL83 for patients with high white blood cell (WBC) count (>2,500/m2) or large tumor burden and was obligatory for all patients in study B-NHL86. Central nervous system (CNS) prophylaxis/treatment consisted of intrathecal methotrexate (MTX) therapy, later extended to the triple combination of MTX, AraC, and dexamethasone, and a CNS irradiation (24 Gy) after the second cycle. Compared with the ALL 01/81 study where all the patients died, results obtained with the pediatric protocols B-NHL83 and B-NHL86 were greatly improved. The complete remission (CR) rates increased from 44% to 63% and 74%, the probability of leukemia free survival (LFS) from 0% to 50% and 71% (P= .04), and the overall survival rates from 0% to 49% and 51% (P= .001). Toxicity, mostly hematotoxicity and mucositis, was severe but manageable. In both studies B-NHL83 and B-NHL86, almost all relapses occurred within 1 year. The time to relapse was different for BM, 92 days, and for isolated CNS and combined BM and CNS relapses, 190 days (P= .08). The overall CNS relapses changed from 50% to 57% and 17%, most probably attributable to the high-dose MTX and the triple intrathecal therapy. LFS in studies B-NHL83 and B-NHL86 was significantly influenced by the initial WBC count < or >50,000/μL, LFS 71% versus 29% (P= .003) and hemoglobin value > or <8 g/dL, LFS 67% versus 27% (P= .02). Initial CNS involvement had no adverse impact on the outcome. Elderly B-ALL patients (>50 years) also benefited from this treatment with a CR rate of 56% and a LFS of 56%. It is concluded that this short intensive therapy with six cycles is effective in adult B-ALL. HdM and fractionated higher doses of cyclophosphamide or ifosphamide seem the two major components of treatment.
- Published
- 1996
- Full Text
- View/download PDF
7. Deoxycoformycin in therapy of refractory lymphoid neoplasms
- Author
-
Ho, Anthony A.D., Thaler, Josef, Kuse, Rolf, Willemze, Roel, Mandelli, Franco, Lauria, Francesco Nicola Icola F., Zittoun, Robert A., Stryckmans, Pierre, Ho, Anthony A.D., Thaler, Josef, Kuse, Rolf, Willemze, Roel, Mandelli, Franco, Lauria, Francesco Nicola Icola F., Zittoun, Robert A., and Stryckmans, Pierre
- Abstract
Knowledge of the vital role of the purine degradative enzyme adenosine deaminase (ADA) in the differentiation of T and B lymphocytes has stimulated interest in the pharmacologic inhibition of ADA as specific cytotoxic therapy for lymphoproliferative diseases. 2' -Deoxycoformycin (DCF) is a tight-binding ADA-inhibitor and has shown activity in T and B cell neoplasms. In this phase-II study, the efficacy and toxicity of DCF in chronic T and B cell neoplasms is investigated. We report the preliminary results of treatment in 27 patients (8 with Sezary syndrome, 11 with B-chronic lymphocytic leukemia (CLL), and 8 with hairy cell leukemia (HCL)), who were refractory to conventional therapy. DCF was applied at a dosage of 4 mg/m2 weekly x 3, then 4 mg/m2 every other week x 3. Three of the 8 patients with Sezary syndrome and 3 of the 11 patients with B-CLL attained a partial remission. One complete and 7 partial remissions have been achieved thus far in the 8 patients with HCL refractory to interferon alpha treatment. Other than nausea in 10 patients (mainly grade 1 and 2), transient skin rash in 4 patients and Herpes infections in 4 patients (mainly grade 2), no other major toxicities were observed. Thus DCF is highly active in hairy cell leukemia that did not respond to interferon alpha, and shows moderate activity in refractory Sezary syndrome and B-CLL. © 1988 S. Karger GmbH, Freiburg., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 1988
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.